Tesamorelin Explained: Visceral Fat Research (Philippines Guide)

Most peptides sold online have never been approved as medicines. Tesamorelin has, for one very specific kind of belly fat. Tesamorelin is a synthetic analog of growth hormone releasing hormone, or GHRH. It copies the signal your brain sends to the pituitary gland.

It fits the GHRH receptor on the pituitary, which then releases more of the body's own growth hormone. What does the research show? Two phase 3 trials enrolled 816 adults with HIV and excess abdominal fat. After 26 weeks, visceral fat, the deep fat around the organs, fell 18 percent in one trial and 14 percent in the other.

Placebo groups changed by about 2 percent. With continued use to 52 weeks, the reduction held. When people stopped, visceral fat tended to return. A 2019 trial in the Lancet HIV followed 61 adults with HIV and fatty liver for a year.

Liver fat fell by 37 percent in relative terms. Side effects in trials included joint pain, injection site redness, swelling and muscle pain. Blood sugar worsened more often than on placebo. Effects in people without HIV are far less studied.

Status: the US FDA approved tesamorelin in 2010, only to reduce excess abdominal fat in adults with HIV and lipodystrophy. Research-grade vials are not that approved medicine. If you are sourcing research peptides in the Philippines, Primara Labs publishes independent lab reports you can verify yourself. Guides at primaralabs.

com.